Anti-GBM Antibody
The Anti-GBM Antibody test measures the level of antibodies targeting the glomerular basement membrane, which can indicate autoimmune kidney disease.
Anti-GBM Antibody titer helps diagnose autoimmune kidney conditions.
Key facts at a glance
- Units
- titer
- Clinical utility
- diagnostic
- Result kind
- qualitative
- FDA-cleared
- Roche Anti-GBM, Abbott Anti-GBM, Euroimmun Anti-GBM
The Anti-GBM Antibody test is a diagnostic tool used to detect the presence of anti-glomerular basement membrane antibodies in the blood. These antibodies attack the kidneys and can cause severe damage if left untreated.
This biomarker is particularly important in diagnosing Goodpasture's syndrome, a rare but serious autoimmune condition that affects both the kidneys and the lungs. Elevated levels of Anti-GBM antibodies are a strong indicator of this disease.
A titer of 0–1 is considered normal, while higher titers suggest the presence of anti-GBM antibodies and warrant further investigation. Early detection and treatment are crucial for preventing irreversible kidney damage.
Frequently asked questions
What is the normal range for Anti-GBM Antibody levels?
What does a high Anti-GBM Antibody titer indicate?
Sources
- 1
- 2
Click any link to access the full source. PubMed Central (PMC) links provide free full-text access.
This information is for educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment.
This content is for general informational and educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Always seek the guidance of a qualified healthcare provider with any questions you have about a medical condition, and never disregard professional medical advice or delay seeking it because of something you read here.
If you think you may have a medical emergency, call your local emergency number or go to the nearest emergency department immediately.
Medically reviewed by WellAlly Editorial Team Last reviewed August 25, 2026. · Read our editorial policy